FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2018086906> ?p ?o ?g. }

• W2018086906 endingPage "308" @default.
• W2018086906 startingPage "301" @default.
• W2018086906 abstract "Objectives: To assess the cost effectiveness of palivizumab, a humanised monoclonal antibody, used as prevention against severe respiratory syncytial virus (RSV) infection requiring hospitalisation, in infants with haemodynamically significant congenital heart disease (CHD) in the German healthcare setting.Study design: A decision-tree model was used to estimate the cost effectiveness of palivizumab for a hypothetical cohort of patients. The analysis was based on a lifetime follow-up period in order to capture the impact of palivizumab on long-term morbidity and mortality resulting from an RSV infection. Data sources included published literature, the palivizumab pivotal trials, official price/tariff lists and national population statistics. The study was conducted from the perspective of society (primary analysis) and the healthcare purchaser (secondary analysis).Results: From the societal perspective, use of palivizumab results in an incremental cost-effectiveness ratio (ICER) of €2,615 per quality-adjusted life-year (QALY) without discounting, which increases to €9,529/QALY after discounting. From the perspective of the German healthcare purchaser, use of palivizumab results in an ICER of €4,576/QALY without discounting, which increases to €16,673/QALY after discounting. Probabilistic sensitivity analyses confirmed the robustness of the model. The study is limited by a number of conservative assumptions. It was assumed that palivizumab only affects the occurrence of RSV hospitalisation and does not influence the severity of the RSV infection. Another assumption was that international clinical trial data and data on utilities could be applied to the German healthcare setting.Conclusion: This analysis showed that palivizumab represents a cost-effective means of prophylaxis against severe RSV infection requiring hospitalisation in infants with haemodynamically significant CHD." @default.
• W2018086906 created "2016-06-24" @default.
• W2018086906 creator A5055580269 @default.
• W2018086906 creator A5062370846 @default.
• W2018086906 creator A5062818266 @default.
• W2018086906 date "2009-10-08" @default.
• W2018086906 modified "2023-10-16" @default.
• W2018086906 title "Cost effectiveness of palivizumab in children with congenital heart disease in Germany" @default.
• W2018086906 cites W1504523720 @default.
• W2018086906 cites W1546471715 @default.
• W2018086906 cites W179697854 @default.
• W2018086906 cites W1966099212 @default.
• W2018086906 cites W1977172254 @default.
• W2018086906 cites W1977888022 @default.
• W2018086906 cites W1994115946 @default.
• W2018086906 cites W1997644723 @default.
• W2018086906 cites W2005761948 @default.
• W2018086906 cites W2009110528 @default.
• W2018086906 cites W2013659785 @default.
• W2018086906 cites W2029503764 @default.
• W2018086906 cites W2036877259 @default.
• W2018086906 cites W2044486890 @default.
• W2018086906 cites W2066295547 @default.
• W2018086906 cites W2079082970 @default.
• W2018086906 cites W2081610092 @default.
• W2018086906 cites W2095078781 @default.
• W2018086906 cites W2096631141 @default.
• W2018086906 cites W2126229640 @default.
• W2018086906 cites W2205355961 @default.
• W2018086906 cites W2312247407 @default.
• W2018086906 cites W4255934323 @default.
• W2018086906 doi "https://doi.org/10.3111/13696990903347172" @default.
• W2018086906 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19811110" @default.
• W2018086906 hasPublicationYear "2009" @default.
• W2018086906 type Work @default.
• W2018086906 sameAs 2018086906 @default.
• W2018086906 citedByCount "18" @default.
• W2018086906 countsByYear W20180869062012 @default.
• W2018086906 countsByYear W20180869062013 @default.
• W2018086906 countsByYear W20180869062014 @default.
• W2018086906 countsByYear W20180869062016 @default.
• W2018086906 countsByYear W20180869062017 @default.
• W2018086906 countsByYear W20180869062018 @default.
• W2018086906 countsByYear W20180869062019 @default.
• W2018086906 countsByYear W20180869062020 @default.
• W2018086906 countsByYear W20180869062023 @default.
• W2018086906 crossrefType "journal-article" @default.
• W2018086906 hasAuthorship W2018086906A5055580269 @default.
• W2018086906 hasAuthorship W2018086906A5062370846 @default.
• W2018086906 hasAuthorship W2018086906A5062818266 @default.
• W2018086906 hasConcept C10138342 @default.
• W2018086906 hasConcept C112930515 @default.
• W2018086906 hasConcept C126322002 @default.
• W2018086906 hasConcept C160735492 @default.
• W2018086906 hasConcept C162324750 @default.
• W2018086906 hasConcept C177713679 @default.
• W2018086906 hasConcept C184834754 @default.
• W2018086906 hasConcept C187212893 @default.
• W2018086906 hasConcept C2778644256 @default.
• W2018086906 hasConcept C2780074459 @default.
• W2018086906 hasConcept C2908647359 @default.
• W2018086906 hasConcept C3019080777 @default.
• W2018086906 hasConcept C50522688 @default.
• W2018086906 hasConcept C515549039 @default.
• W2018086906 hasConcept C534529494 @default.
• W2018086906 hasConcept C6177178 @default.
• W2018086906 hasConcept C71924100 @default.
• W2018086906 hasConcept C99454951 @default.
• W2018086906 hasConceptScore W2018086906C10138342 @default.
• W2018086906 hasConceptScore W2018086906C112930515 @default.
• W2018086906 hasConceptScore W2018086906C126322002 @default.
• W2018086906 hasConceptScore W2018086906C160735492 @default.
• W2018086906 hasConceptScore W2018086906C162324750 @default.
• W2018086906 hasConceptScore W2018086906C177713679 @default.
• W2018086906 hasConceptScore W2018086906C184834754 @default.
• W2018086906 hasConceptScore W2018086906C187212893 @default.
• W2018086906 hasConceptScore W2018086906C2778644256 @default.
• W2018086906 hasConceptScore W2018086906C2780074459 @default.
• W2018086906 hasConceptScore W2018086906C2908647359 @default.
• W2018086906 hasConceptScore W2018086906C3019080777 @default.
• W2018086906 hasConceptScore W2018086906C50522688 @default.
• W2018086906 hasConceptScore W2018086906C515549039 @default.
• W2018086906 hasConceptScore W2018086906C534529494 @default.
• W2018086906 hasConceptScore W2018086906C6177178 @default.
• W2018086906 hasConceptScore W2018086906C71924100 @default.
• W2018086906 hasConceptScore W2018086906C99454951 @default.
• W2018086906 hasIssue "4" @default.
• W2018086906 hasLocation W20180869061 @default.
• W2018086906 hasLocation W20180869062 @default.
• W2018086906 hasOpenAccess W2018086906 @default.
• W2018086906 hasPrimaryLocation W20180869061 @default.
• W2018086906 hasRelatedWork W2001644930 @default.
• W2018086906 hasRelatedWork W2007406459 @default.
• W2018086906 hasRelatedWork W2041710893 @default.
• W2018086906 hasRelatedWork W2165816433 @default.
• W2018086906 hasRelatedWork W2371007886 @default.
• W2018086906 hasRelatedWork W3155279848 @default.
• W2018086906 hasRelatedWork W4231568911 @default.

• next